Business
Non-Executive Director Appointment
Non-Executive Director Appointment.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3379F\n Oxford Biomedica PLC\n 15 July 2021\n \n \n \n \n \n \n \n Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director\n \n \n \n \n \n Oxford, UK - 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Group\"), a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group's Board as a Non-Executive Director, effective today.\n \n Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals Industries Ltd. from 2012 to 2017 during which time approximately 35 new products were approved in major markets. In 2015 Teva R&D was recognised as one of the ten most exciting innovators in the pharma sector and in 2017 it was ranked top of the industry for CNS development and clinical trial success rate by Pharma Intelligence.1\n \n Dr. Hayden is the co-founder of five biotechnology companies: Prilenia Therapeutics B.V., NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp and 89bio, Inc. He currently represents various private biotech companies at Board level and serves as CEO of Prilenia Therapeutics, which is a private company focussed on the neurology space. In addition he is, or has been, on the Board of the following public companies in the last five years: 89bio, Inc., AbCellera Biologics Inc., Aurinia Pharmaceuticals Inc (until 30 June 2021), Ionis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.\n \n Dr. Hayden has previously been cited as one of the 50 Canadians born in the 20th century to have changed the world2, and in 2017 was inducted into the Canadian Medical Hall of Fame. He has authored approximately 900 peer-reviewed publications and invited submissions, and has focused his research primarily on translational medicine, including genetics of diabetes, lipoprotein disorders, Huntington's disease, predictive and personalised medicine, and drug development. Dr. Hayden and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. He also identified the first mutations underlying Lipoprotein Lipase (LPL) deficiency and developed gene therapy approaches to treat this condition resulting in...